Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-CLDN18.2
- Development stage
- Unknown
- Lead developer
- PDRadiopharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
64Cu-CLDN18.2 (also known as 64Cu-PD-29875 or PD-29875D) is a claudin 18.2 (CLDN18.2)-targeted diagnostic radiopharmaceutical developed by PeptiDream and its wholly owned subsidiary, PDRadiopharma. It consists of a macrocyclic peptide ligand (PD-29875) discovered using PeptiDream's proprietary Peptide Discovery Platform System (PDPS®) technology, labeled with the positron-emitting radioisotope copper-64 (64Cu). 64Cu-CLDN18.2 is designed as a positron emission tomography (PET) imaging agent to visualize CLDN18.2-expressing tumors, particularly in gastric cancer and gastroesophageal junction cancer. It serves as a diagnostic companion in a theranostic pair alongside its actinium-225 (225Ac)-labeled therapeutic counterpart (PD-29875T). 64Cu-CLDN18.2 is currently undergoing Phase 0/first-in-human clinical imaging studies in patients with gastric cancer.
- Other names
- 64Cu-labeled Claudin 18.2-targeting cyclic peptide64Cu-labeled Claudin 18.2-targeting macrocyclic peptide
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on 64Cu-CLDN18.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-CLDN18.2.